ChemGenex Pharmaceuticals Limited Presents Updated Analysis at American Society of Hematology on OMAPRO(TM) in CML Patients Who Failed Two or Three Approved TKI Drugs

Published: Dec 06, 2010

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced yesterday the presentation of updated clinical data showing that OMAPRO™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in a significant proportion of chronic phase chronic myeloid leukemia (CML) patients, who had failed previous attempts to control their disease with two or three FDA-approved tyrosine kinase inhibitors (TKIs). The new data were presented at the 52nd Annual American Society of Hematology Meeting in Orlando, Florida (ASH).

Back to news